Comparison  ||| S:0 E:11 ||| NN
of  ||| S:11 E:14 ||| IN
cardiovascular  ||| S:14 E:29 ||| JJ
risk  ||| S:29 E:34 ||| NN
in  ||| S:34 E:37 ||| IN
ankylosing  ||| S:37 E:48 ||| JJ
spondylitis  ||| S:48 E:60 ||| NN
and  ||| S:60 E:64 ||| CC
rheumatoid  ||| S:64 E:75 ||| JJ
arthritis  ||| S:75 E:85 ||| NN
Cardiovascular  ||| S:85 E:100 ||| NNP
co-morbidity  ||| S:100 E:113 ||| NNP
is  ||| S:113 E:116 ||| VBZ
now  ||| S:116 E:120 ||| RB
a  ||| S:120 E:122 ||| DT
recognised  ||| S:122 E:133 ||| JJ
complication  ||| S:133 E:146 ||| NN
of  ||| S:146 E:149 ||| IN
chronic  ||| S:149 E:157 ||| JJ
inflammation  ||| S:157 E:170 ||| NN
and  ||| S:170 E:174 ||| CC
an  ||| S:174 E:177 ||| DT
elevated  ||| S:177 E:186 ||| JJ
acute  ||| S:186 E:192 ||| JJ
phase  ||| S:192 E:198 ||| NN
response  ||| S:198 E:207 ||| NN
predisposes  ||| S:207 E:219 ||| NN
to  ||| S:219 E:222 ||| TO
hypertension ||| S:222 E:234 ||| VB
,  ||| S:234 E:236 ||| ,
stroke  ||| S:236 E:243 ||| NN
and  ||| S:243 E:247 ||| CC
myocardial  ||| S:247 E:258 ||| JJ
infarction ||| S:258 E:268 ||| NN
.  ||| S:268 E:270 ||| .
Dyslipidaemia  ||| S:270 E:284 ||| NNP
is  ||| S:284 E:287 ||| VBZ
a  ||| S:287 E:289 ||| DT
feature  ||| S:289 E:297 ||| NN
of  ||| S:297 E:300 ||| IN
inflammatory  ||| S:300 E:313 ||| JJ
joint  ||| S:313 E:319 ||| JJ
diseases  ||| S:319 E:328 ||| NNS
and  ||| S:328 E:332 ||| CC
is  ||| S:332 E:335 ||| VBZ
closely  ||| S:335 E:343 ||| RB
related  ||| S:343 E:351 ||| VBN
to  ||| S:351 E:354 ||| TO
elevated  ||| S:354 E:363 ||| VB
CRP  ||| S:363 E:367 ||| NNP
and  ||| S:367 E:371 ||| CC
Il-6  ||| S:371 E:376 ||| CD
levels ||| S:376 E:382 ||| NNS
.  ||| S:382 E:384 ||| .
Rheumatoid  ||| S:384 E:395 ||| JJ
arthritis  ||| S:395 E:405 ||| NN
( ||| S:405 E:406 ||| -LRB-
RA ||| S:406 E:408 ||| NNP
)  ||| S:408 E:410 ||| -RRB-
has  ||| S:410 E:414 ||| VBZ
an  ||| S:414 E:417 ||| DT
increased  ||| S:417 E:427 ||| JJ
standardised  ||| S:427 E:440 ||| JJ
mortality  ||| S:440 E:450 ||| NN
ratio  ||| S:450 E:456 ||| NN
largely  ||| S:456 E:464 ||| RB
attributable  ||| S:464 E:477 ||| JJ
to  ||| S:477 E:480 ||| TO
cardiovascular  ||| S:480 E:495 ||| JJ
risk ||| S:495 E:499 ||| NN
.  ||| S:499 E:501 ||| .
An  ||| S:501 E:504 ||| DT
increased  ||| S:504 E:514 ||| VBN
although  ||| S:514 E:523 ||| IN
lesser ||| S:523 E:529 ||| JJR
,  ||| S:529 E:531 ||| ,
cardiovascular  ||| S:531 E:546 ||| JJ
morbidity  ||| S:546 E:556 ||| NN
has  ||| S:556 E:560 ||| VBZ
also  ||| S:560 E:565 ||| RB
been  ||| S:565 E:570 ||| VBN
observed  ||| S:570 E:579 ||| VBN
in  ||| S:579 E:582 ||| IN
ankylosing  ||| S:582 E:593 ||| JJ
spondylitis  ||| S:593 E:605 ||| NNS
( ||| S:605 E:606 ||| -LRB-
AS ||| S:606 E:608 ||| NNP
)  ||| S:608 E:610 ||| -RRB-
which  ||| S:610 E:616 ||| WDT
has  ||| S:616 E:620 ||| VBZ
a  ||| S:620 E:622 ||| DT
similar  ||| S:622 E:630 ||| JJ
abnormal  ||| S:630 E:639 ||| JJ
lipid  ||| S:639 E:645 ||| JJ
profile  ||| S:645 E:653 ||| NN
to  ||| S:653 E:656 ||| TO
that  ||| S:656 E:661 ||| DT
seen  ||| S:661 E:666 ||| VBN
in  ||| S:666 E:669 ||| IN
RA ||| S:669 E:671 ||| NNP
.  ||| S:671 E:673 ||| .
There  ||| S:673 E:679 ||| EX
is  ||| S:679 E:682 ||| VBZ
some  ||| S:682 E:687 ||| DT
evidence  ||| S:687 E:696 ||| NN
that  ||| S:696 E:701 ||| IN
therapeutic  ||| S:701 E:713 ||| JJ
agents  ||| S:713 E:720 ||| NNS
such  ||| S:720 E:725 ||| JJ
as  ||| S:725 E:728 ||| IN
anti-tumour  ||| S:728 E:740 ||| JJ
necrosis  ||| S:740 E:749 ||| JJ
factor-alpha  ||| S:749 E:762 ||| NN
( ||| S:762 E:763 ||| -LRB-
TNF-alpha ||| S:763 E:772 ||| NNP
)  ||| S:772 E:774 ||| -RRB-
drugs  ||| S:774 E:780 ||| NNS
that  ||| S:780 E:785 ||| IN
down-regulate  ||| S:785 E:799 ||| JJ
the  ||| S:799 E:803 ||| DT
acute  ||| S:803 E:809 ||| JJ
phase  ||| S:809 E:815 ||| NN
response ||| S:815 E:823 ||| NN
,  ||| S:823 E:825 ||| ,
also  ||| S:825 E:830 ||| RB
have  ||| S:830 E:835 ||| VB
an  ||| S:835 E:838 ||| DT
effect  ||| S:838 E:845 ||| NN
in  ||| S:845 E:848 ||| IN
reducing  ||| S:848 E:857 ||| VBG
cardiovascular  ||| S:857 E:872 ||| JJ
complications  ||| S:872 E:886 ||| NNS
in  ||| S:886 E:889 ||| IN
RA  ||| S:889 E:892 ||| NNP
and  ||| S:892 E:896 ||| CC
AS ||| S:896 E:898 ||| NNP
.  ||| S:898 E:900 ||| .
